What is the recommended treatment strategy for a patient with elevated lipoprotein(a) and high atherosclerotic cardiovascular risk?

Treatment of Elevated Lipoprotein(a)

For patients with elevated lipoprotein(a) [Lp(a) ≥50 mg/dL or ≥125 nmol/L], the primary treatment strategy is aggressive management of all modifiable cardiovascular risk factors, particularly LDL-cholesterol lowering with high-intensity statins combined with ezetimibe, and consideration of PCSK9 inhibitors when LDL-C targets are not achieved. 1

Screening and Risk Stratification

• Measure Lp(a) once in a lifetime as part of initial lipid screening in all adults 1
• Lp(a) testing does not need to be repeated, as levels are genetically determined and remain stable throughout life 2
• Consider Lp(a) measurement particularly in patients with:
  • Premature cardiovascular disease without evident risk factors 3
  • Family history of premature atherosclerotic cardiovascular disease 2, 4
  • Familial hypercholesterolemia 5, 4
  • Recurrent cardiovascular events despite optimal lipid-lowering therapy 5, 4

Primary Prevention Strategy

For Patients with Elevated Lp(a) Without Established ASCVD

Intensify cardiovascular risk factor management earlier and more aggressively than in patients with normal Lp(a) levels 1:

• Lifestyle modifications: Smoking cessation, healthy diet emphasizing vegetables, fruits, whole grains, and polyunsaturated fats; achieve healthy weight (BMI <25 kg/m²); regular physical activity 6
• Aggressive LDL-C lowering: Initiate high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) earlier than would otherwise be indicated 1, 5
• Consider adding ezetimibe if LDL-C remains >2.6 mmol/L (100 mg/dL) on maximally tolerated statin 5
• Blood pressure control: Target <140/90 mm Hg with lifestyle modifications and medications as needed 7
• Consider aspirin for primary prevention in patients with Lp(a) >50 mg/dL, as emerging evidence suggests approximately 50% reduction in coronary heart disease events with aspirin use in this population 8

Risk Enhancement Considerations

Elevated Lp(a) should be used as a risk-enhancing factor to guide treatment decisions 9, 1:

• In patients with 10-year ASCVD risk ≥7.5% and Lp(a) ≥50 mg/dL, consider more intensive LDL-C lowering targets 9
• Consider coronary artery calcium scoring when risk assessment remains uncertain despite elevated Lp(a) 2
• Patients with Lp(a) ≥50 mg/dL fall into a higher risk category and warrant earlier intervention 3

Secondary Prevention Strategy

For Patients with Established ASCVD and Elevated Lp(a)

Implement maximal LDL-C lowering with combination therapy targeting LDL-C <1.8 mmol/L (<70 mg/dL) or <1.4 mmol/L (<55 mg/dL) for very high-risk patients 10, 1:

1. Start with high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) immediately 10

2. Add ezetimibe if LDL-C remains above target after 4-6 weeks 10, 1

3. Add PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) if LDL-C still not at target after another 4-6 weeks on statin plus ezetimibe 10, 1

   • PCSK9 inhibitors reduce Lp(a) by 20-25% in addition to LDL-C lowering 1, 11
   • Post-hoc analyses from FOURIER and ODYSSEY OUTCOMES trials suggest Lp(a) reduction with PCSK9 inhibitors may contribute to cardiovascular benefit 1, 12

4. Consider prolonged dual antiplatelet therapy in secondary prevention settings, as elevated Lp(a) may enhance thrombotic risk 13

Special Populations

For patients with ASCVD and diabetes/metabolic disorders:

• Consider pitavastatin with ezetimibe or lower-dose high-intensity statin (rosuvastatin 20 mg or atorvastatin 40 mg) with ezetimibe to minimize new-onset diabetes risk while achieving LDL-C reduction 10
• Add bempedoic acid if available, which may help optimize both LDL-C and glucose control 10

Current Limitations and Future Directions

What Does NOT Lower Lp(a) Effectively

• Statins: May modestly increase Lp(a) levels and do not reduce Lp(a)-mediated ASCVD risk 1, 11
• Ezetimibe: Does not appreciably lower Lp(a) 1
• Lifestyle modifications: Diet and exercise have little to no effect on Lp(a) levels 11

Available Options with Modest Lp(a) Reduction

• PCSK9 inhibitors: Reduce Lp(a) by 20-25%, though clinical benefit specifically from Lp(a) reduction remains uncertain 1, 11
• Niacin: Lowers Lp(a) by 30-35%, but effectiveness in mitigating Lp(a)-mediated ASCVD risk is unclear and side effects limit use 3, 11
• Lipoprotein apheresis: Reduces Lp(a) up to 80% but is invasive, time-intensive, and costly; reserved for very high Lp(a) with progressive cardiovascular disease despite optimal management 3, 14

Emerging Therapies

Targeted Lp(a)-lowering therapies are in phase 3 clinical development 15, 11:

• Small interfering RNA agents (olpasiran, SLN360) and antisense oligonucleotides (pelacarsen) block apo(a) synthesis and substantially reduce Lp(a) levels 11
• These agents may provide definitive evidence for cardiovascular benefit from Lp(a) lowering in the near future 14, 16, 17

Key Clinical Pitfalls

• Do not delay treatment while waiting for Lp(a)-specific therapies; elevated Lp(a) is actionable now through aggressive risk factor management 13
• Do not repeat Lp(a) measurements unless patient is on specific Lp(a)-lowering therapy, as levels are genetically determined 1, 2
• Do not assume LDL-C lowering alone is sufficient; elevated Lp(a) confers residual risk even when LDL-C is at target 4, 14
• Recognize that event rates remain higher at any achieved LDL-C level when Lp(a) is elevated, emphasizing the need for comprehensive risk factor control 4